|
|
Article: Panel backs candesartan--ACE inhibitor combo.(Cardiovascular Medicine)
- Article from:
- Family Practice News
- Article date:
- April 15, 2005
- Author:
CopyrightCOPYRIGHT 2005 International Medical News Group. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
ROCKVILLE, MD. -- The angiotensin receptor blocker candesartan should be approved as a treatment for heart failure in patients who are on an ACE inhibitor, a Food and Drug Administration advisory panel has recommended.
At a meeting of the FDA's cardiovascular and renal drugs advisory committee, all eight panel members backed approval of such an indication for candesartan on the basis of results of one of the three Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) trials.
In CHARM--Added, candesartan (titrated to a target dose of 32 mg/day) was compared with placebo in 2,548 patients with New York Heart Association ...